IGF-1 LR3 and Tesamorelin Stack: How the Two Compounds Compare

The IGF-1 LR3 and tesamorelin stack combines a growth hormone-releasing hormone (GHRH) analog with a long-acting insulin-like growth factor 1 (IGF-1) analog. Tesamorelin signals the pituitary to release growth hormone, while IGF-1 LR3 acts downstream by mimicking the growth factor that growth hormone ultimately produces. The appeal is hitting the GH/IGF-1 axis from both ends, but that same overlap means the combination can push IGF-1 levels higher than either compound would alone, and no human trial has tested the pair together.

What Each Compound Does

Tesamorelin, sold under the brand name Egrifta, is a synthetic GHRH analog. It binds GHRH receptors in the pituitary and prompts pulsatile growth hormone release, which raises endogenous IGF-1 as a downstream effect.

IGF-1 LR3 is a modified IGF-1 molecule with a longer half-life and reduced binding to IGF-binding proteins. It skips the pituitary step entirely and delivers growth factor signaling directly to IGF-1 receptors in muscle, bone, and other tissue.

Feature	Tesamorelin	IGF-1 LR3
Class	GHRH analog	IGF-1 analog
Primary action	Stimulates pituitary GH release	Acts directly on IGF-1 receptors
Reported half-life	Roughly 26-38 minutes	Roughly 20-30 hours
FDA status	Approved for HIV-associated lipodystrophy	Not approved for human use
Common discussion use	Visceral fat reduction, GH axis support	Muscle growth, recovery, nutrient partitioning

Why People Consider Combining Them

The logic behind the stack is complementary action rather than a larger dose of one compound. Tesamorelin works on the upstream signal, and IGF-1 LR3 supplies the downstream product.

Forum discussions, including many tesamorelin and igf-1 lr3 stack reddit threads, usually describe two goals: visceral fat reduction from the GHRH side and muscle growth or recovery from the IGF-1 side.

A second motivation is limiting growth hormone exposure. Some users reason that a modest tesamorelin dose plus a small amount of IGF-1 LR3 achieves more than a high dose of either one alone.

Timing and Dosing Considerations

No controlled human study has tested IGF-1 LR3 and tesamorelin together, so every schedule in circulation comes from anecdotal reports rather than clinical data. The figures below describe how each compound is used in research or described in user logs, and they are not a recommended protocol.

Compound	Reported or studied dose	Reported timing	Evidence level
Tesamorelin	1-2 mg subcutaneously daily	Once daily, often at night	Clinical trials in HIV lipodystrophy
IGF-1 LR3	20-50 mcg per day in forum reports	Once daily, often after training	No established human dosing

Because IGF-1 LR3 supplies the end product of the GH axis, taking full doses of both compounds can push IGF-1 far above the normal range. Checking IGF-1 and fasting glucose with lab work is the only way to know where levels actually sit.

How It Compares With Other Stacking Options

If you are asking What to stack with IGF-1 LR3?, most online answers point to GHRH analogs such as CJC-1295, mod GRF(1-29), or tesamorelin itself, since they raise the same axis from above.

A side-by-side tesamorelin vs igf-1 lr3 comparison comes down to position on the axis: one increases the signal, and the other replaces the output.

The tesamorelin and cjc-1295 stack pairs two GHRH analogs, which many researchers consider redundant because both act on the same pituitary receptor.

The tesamorelin and sermorelin stack follows similar logic, with the two compounds differing mainly in half-life and potency.

The tesamorelin and bpc-157 stack is different again, because BPC-157 is studied for tissue repair and gut lining support rather than for the GH/IGF-1 axis.

Stack	Primary target	Overlap concern
Tesamorelin + IGF-1 LR3	GH release plus direct IGF-1 signaling	Additive IGF-1 elevation
Tesamorelin + CJC-1295	Two GHRH analogs	Same receptor, likely redundant
Tesamorelin + BPC-157	GH axis plus tissue repair	Little documented interaction

Risks, Side Effects, and Legal Status

Both compounds carry real side effect profiles, and stacking them compounds the uncertainty rather than the benefit. Nothing about combining them reduces the risks that each one carries on its own.

• Tesamorelin: injection-site reactions, joint pain, peripheral swelling, and elevated IGF-1 levels. It is not appropriate for people with pituitary tumors or active cancer.
• IGF-1 LR3: hypoglycemia, jaw and joint pain, fluid retention, and unanswered questions about tissue growth. It is not approved for human use.
• Combined: sustained supraphysiologic IGF-1, which is linked to acromegalic symptoms such as enlarged hands, feet, and jaw, along with metabolic strain.

Tesamorelin is FDA-approved only for excess abdominal fat in adults with HIV-associated lipodystrophy, and IGF-1 LR3 is not approved for any human use in the United States.

Blood sugar monitoring matters because IGF-1 lowers glucose, and the effect can stack with insulin or other glucose-lowering drugs. Anyone with diabetes, prediabetes, or a personal or family history of cancer should avoid experimenting with this combination outside medical supervision.

Practical Takeaways

• The IGF-1 LR3 and tesamorelin stack targets the same axis from two directions, which raises IGF-1 more than either compound alone.
• No human trial has evaluated the combination, so dosing and timing claims online are anecdotal.
• Tesamorelin has a narrow FDA-approved indication, and IGF-1 LR3 has none.
• Lab monitoring of IGF-1 and glucose is the practical minimum for anyone using either compound under a physician's care.
• Prescription medications, including GHRH analogs used for approved indications, should only be used under the direction of a licensed healthcare professional.

For most people reading about igf 1 tesamorelin protocols online, the honest summary is that the science is thin, the regulatory picture is restrictive, and the side effect overlap is real. A conversation with a physician beats any forum protocol.

COMMON QUESTIONS

Frequently Asked Questions

Can you stack IGF-1 LR3 with tesamorelin?

No clinical protocol exists for combining IGF-1 LR3 with tesamorelin, and no human trial has tested the pair. Tesamorelin raises growth hormone and therefore IGF-1, while IGF-1 LR3 adds a long-acting IGF-1 analog directly, so the combination can push IGF-1 well above the normal range. Anyone considering it should discuss it with a physician and have IGF-1 and glucose levels checked.

Is tesamorelin the same thing as IGF-1 LR3?

No. Tesamorelin is a GHRH analog approved by the FDA as Egrifta to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, and it works by stimulating pituitary growth hormone release. IGF-1 LR3 is a long-acting IGF-1 analog that is not FDA-approved for human use and acts directly on IGF-1 receptors rather than on the pituitary.

How long does IGF-1 LR3 stay in your system compared with tesamorelin?

IGF-1 LR3 is designed for a long half-life, commonly reported at roughly 20 to 30 hours in circulation, which is why once-daily dosing is often discussed in user logs. Tesamorelin has a much shorter half-life of about 26 to 38 minutes, though its downstream effect on growth hormone and IGF-1 lasts considerably longer than the drug itself.